# A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

> **NCT04392700** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 706 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Recurrent

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate 300mg
- **DRUG:** Entecavir 0.5 mg

## Key facts

- **NCT ID:** NCT04392700
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-25
- **Primary completion:** 2021-07-25
- **Final completion:** 2024-07-25
- **Target enrollment:** 706 (ESTIMATED)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04392700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04392700, "A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04392700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*